7-乙基-1-苯并噻吩 | 16587-42-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 7-乙基-1-苯并噻吩
• 英文名称: 7-ethylbenzothiophene
• 英文别名: 7-ethyl-benzo[b]thiophene；7-Ethyl-1-benzothiophene
• CAS: 16587-42-1
• 化学式: C₁₀H₁₀S
• 分子量: 162.255
• InChiKey: SZNQHLOLUMHNIM-UHFFFAOYSA-N

物化性质

• 沸点：
  257.6±9.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)
• 保留指数：
  1378.3

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  五羰基溴化锰(I) 、 7-乙基-1-苯并噻吩 、 silver tetrafluoroborate 以 二氯甲烷 为溶剂， 以84%的产率得到[manganese tricarbonyl (7-ethylbenzothiophene)](BF4)
  参考文献：
  名称：

  苯并噻吩均相加氢脱硫的模型：锰顺序插入到C（芳基）-S和C（乙烯基）-S键中，然后是金属硫杂环丁烷环收缩

  摘要：

  Mn（CO）3 +与苯并噻吩的碳环配位会激活C（芳基）-S键还原性裂解，从而提供金属硫环5。当在7-R取代5为甲基或乙基的（但不是氢），快速C（乙烯基）-S键断裂随之而来，得到异构体6，其随后经历metallathiacycle环收缩，以产生复杂7。

  DOI：

  10.1021/om970728x

文献信息

• ALLOSTERIC BINDING COMPOUNDS
  申请人：Neubauer Henrik Amtoft

  公开号：US20120095048A1

  公开（公告）日：2012-04-19

  The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.

  本发明涉及具有公式(I)的变构结合化合物，尤其用于治疗中枢神经系统疾病，以及包含这些化合物的药物组合物和治疗方法。
• [EN] THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE THIAZOLOPYRIMIDINONE COMME INHIBITEURS DE LA KINASE PI3
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010135504A1

  公开（公告）日：2010-11-25

  This invention relates to the use of thiazolopyrimidinone derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3' OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of thiazolopyrimidinones in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective thiazolopyrimidinones compounds for treating cancer.

  这项发明涉及噻唑吡咯嘧啶酮衍生物在调节磷脂酰肌醇3' OH激酶家族（以下简称PI3激酶）的活性或功能，特别是抑制其活性或功能方面的用途，适当地，PI3Kα、PI3Kδ、PI3Kβ和/或PI3Kγ。适当地，本发明涉及噻唑吡咯嘧啶酮在治疗以下一种或多种疾病状态中的用途：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活动力、移植排斥、移植物排斥和肺部损伤。更适当地，本发明涉及PI3Kβ选择性噻唑吡咯嘧啶酮化合物用于治疗癌症。
• POLYMERIZABLE MONOMER, POLYMER COMPOUND FOR CONDUCTIVE POLYMER, AND METHOD FOR PRODUCING THE POLYMER COMPOUND
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20200247926A1

  公开（公告）日：2020-08-06

  Polymerization reaction is performed using a polymerizable monomer shown by the following general formula (1) and at least one monomer selected from monomers each having a structure of a salt among a lithium salt, a sodium salt, a potassium salt, and a nitrogen compound salt of a fluorosulfonic acid or the like; then, the structure of the salt of the repeating unit of a polymer obtained by the polymerization reaction is changed to the fluorosulfonic acid or the like by ion exchange. Thus, the present invention provides a polymer compound for a conductive polymer and a method for producing the polymer compound which is suitably used as a dopant for a fuel cell and a conductive material, and which is a copolymer containing a repeating unit of styrene having a 3,3,3-trifluoro-2-hydroxy-2-trifluoromethylisobutyl ether group, and a repeating unit having any of a fluorosulfonic acid, a fluorosulfonimide group, and a n-carbonyl-fluoro-sulfonamide group.

  聚合反应使用以下一般式（1）所示的可聚合单体和至少一种选择自锂盐、钠盐、钾盐和氟磺酸盐等盐结构的单体中的单体进行；然后，通过离子交换将聚合反应得到的聚合物的重复单元的盐结构改变为氟磺酸盐或类似物。因此，本发明提供了一种用作导电聚合物的聚合物化合物以及用作燃料电池和导电材料的掺杂剂的聚合物化合物的生产方法，该聚合物是含有3,3,3-三氟-2-羟基-2-三氟甲基异丁基醚基的苯乙烯重复单元和具有氟磺酸、氟磺酰亚胺基团和n-羰基-氟磺酰胺基团中的任何一种的重复单元的共聚物。
• Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same
  申请人：Kim Seon Mi

  公开号：US20130137661A1

  公开（公告）日：2013-05-30

  Disclosed are compounds useful as gonadotrophin-releasing hormone (“GnRH”) receptor antagonist.

  披露了作为促性腺激素释放激素（“GnRH”）受体拮抗剂有用的化合物。
• [EN] GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'HORMONE DE LIBÉRATION DES GONADOTROPHINES, LEUR PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：SK CHEMICALS CO LTD

  公开号：WO2013129879A1

  公开（公告）日：2013-09-06

  The present invention provides gonadotropin releasing hormone receptor antagonists and the pharmaceutical composition comprising the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as Alzheimer disease.

  本发明提供了促性腺激素释放激素受体拮抗剂及包括其的药物组合物，可用于预防或治疗与性激素相关的疾病，如子宫内膜异位症、闭经、月经不调、子宫肌瘤、子宫肌瘤、多囊卵巢综合征、红斑狼疮、多毛症、性早熟、身材矮小、痤疮、脱发、性腺类固醇依赖性肿瘤、促性腺激素产生性垂体腺瘤、睡眠呼吸暂停、肠易激综合征、经前综合征、良性前列腺增生、避孕和不孕症，以及阿尔茨海默病。